# Correction: The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks

**Authors:** Frederick A. Sirgel, Robin M. Warren, Erik C. Böttger, Marisa Klopper, Thomas C. Victor, Paul D. van Helden

PMC · DOI: 10.1371/journal.pone.0134190 · PLoS ONE · 2015-07-21

## Full-text entities

- **Genes:** rpoB [NCBI Gene 888164]
- **Diseases:** Tuberculosis (MESH:D014376), MDR (MESH:D018088)
- **Chemicals:** Rifabutin (MESH:D017828), Rifampicin (MESH:D012293)
- **Species:** Mycobacterium tuberculosis (species) [taxon 1773]
- **Mutations:** D516Y, D516S, S531L, D516V, Q510P, D516T

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC4510876/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC4510876/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC4510876/full.md

---
Source: https://tomesphere.com/paper/PMC4510876